Adlai Nortye Ltd.

NasdaqGM:ANL Stock Report

Market Cap: US$76.8m

Adlai Nortye Valuation

Is ANL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Share Price vs Fair Value

What is the Fair Price of ANL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ANL?

Key metric:

The above table shows the Price to Sales ratio for ANL. This is calculated by dividing ANL's market cap by their current revenue.
What is ANL's PS Ratio?
PS Ratio15.1x
SalesUS$5.00m
Market CapUS$76.84m

Price to Sales Ratio vs Peers

How does ANL's PS Ratio compare to its peers?

The above table shows the PS ratio for ANL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average11.4x
MRSN Mersana Therapeutics
1.8x34.9%US$65.2m
AGEN Agenus
0.5x11.4%US$85.9m
ARMP Armata Pharmaceuticals
14.4x0.3%US$79.2m
IPSC Century Therapeutics
28.8x18.6%US$75.8m
ANL Adlai Nortye
15.1x-122.1%US$76.8m

Price to Sales Ratio vs Industry

How does ANL's PS Ratio compare vs other companies in the US Biotechs Industry?

134 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.2x1.3%US$20.80b
MRNA Moderna
3.2x11.4%US$14.82b
INCY Incyte
3.4x5.4%US$13.95b
EXAS Exact Sciences
3.8x9.6%US$10.14b
ANL 15.1xIndustry Avg. 10.2xNo. of Companies134PS01632486480+
134 CompaniesEstimated GrowthMarket Cap
No more companies

Price to Sales Ratio vs Fair Ratio

What is ANL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ANL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio15.1x
Fair PS Ratio0.03x

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Price Target
Consensus Narrative from 1 Analyst
US$9.00
Fair Value
77.2% undervalued intrinsic discount
1
Number of Analysts

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 01:34
End of Day Share Price 2025/01/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adlai Nortye Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.